Annexon Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference
Rhea-AI Summary
Annexon (Nasdaq: ANNX) announced that Douglas Love, president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 a.m. PST. A live webcast will be available under the Events & Presentations section on the company’s Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
Positive
- None.
Negative
- None.
News Market Reaction 37 Alerts
On the day this news was published, ANNX gained 8.43%, reflecting a notable positive market reaction. Argus tracked a peak move of +10.8% during that session. Our momentum scanner triggered 37 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $65M to the company's valuation, bringing the market cap to $832M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
ANNX was down 2.3% pre-news while key neuroscience/biotech peers were mixed: NMRA +8.33%, ALEC +6.96%, LCTX +
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 16 | Inducement grant | Neutral | +2.1% | New employee stock option grant under inducement plan. |
| Nov 14 | Offering closing | Negative | +11.4% | Closed equity offering with full underwriter option exercise. |
| Nov 12 | Offering pricing | Negative | -4.4% | Priced public offering of stock and pre-funded warrants. |
| Nov 12 | Offering announcement | Negative | -4.4% | Announced proposed $75M equity and warrant offering. |
| Nov 10 | Earnings & pipeline | Positive | -0.3% | Q3 2025 results and late-stage pipeline/milestone update. |
Offerings and financings often drew meaningful price moves, with one closing rallying despite typically dilutive dynamics, while earnings and proposed offerings saw modest pressure.
Over the last few months, Annexon announced multiple financings and an earnings update. In November 2025, it proposed and then priced a public offering around $75M, followed by closing the deal with gross proceeds of $86.25M, which produced both aligned and divergent price reactions. Q3 2025 results on Nov 10 highlighted a cash balance of $188.7M and portfolio milestones with only a small share-price move. A December inducement grant to a new employee had limited but positive impact, framing today’s conference appearance as part of ongoing investor outreach.
Market Pulse Summary
The stock moved +8.4% in the session following this news. A strong positive reaction aligns with the company’s positioning before the event: shares traded at $5.10, above the $2.80 200-day MA and well off the $1.285 52-week low, reflecting prior financing and portfolio progress. Historically, Annexon’s news has produced mixed reactions, with offerings sometimes rallying. Investors might weigh how much of the conference message was already reflected in these earlier financings and earnings disclosures.
Key Terms
immunotherapies medical
neuroinflammatory medical
AI-generated analysis. Not financial advice.
BRISBANE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that Douglas Love, president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 11:15 a.m. PST.
A live webcast of the event can be accessed under the ‘Events & Presentations’ section on the Investors page at www.annexonbio.com. A replay of the webcast will be archived on the Annexon website for 30 days following the presentation.
About Annexon
Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
Media Contact:
Beth Keshishian
917-912-7195
beth@bethkeshishian.com
FAQ
When will Annexon (ANNX) present at the J.P. Morgan Healthcare Conference?
How can investors watch Annexon (ANNX) live at the J.P. Morgan presentation?
Will Annexon (ANNX) provide a replay of the J.P. Morgan presentation and for how long?
Who from Annexon (ANNX) will present at the J.P. Morgan Healthcare Conference?
Does Annexon (ANNX) announcement list the presentation topics or slides?
